Transplant rejection
MONDO:1010185A disease related to transplantation that occurs when transplant tissue is rejected by the recipient's immune system, which destroys the transplanted tissue.
Also known as: host versus graft disease, host vs graft disease
147 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug aimed at stopping lung rejection in transplant patients
Disease control Not yet recruitingThis early-stage trial tests a drug called fostamatinib in 30 adults who have developed donor-specific antibodies after a lung transplant. These antibodies can attack the new lung and raise the risk of death. Participants take fostamatinib or a placebo for 8 weeks, along with the…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aims to stop kidney transplant rejection
Disease control Not yet recruitingThis study tests a new medicine called CID-103 in adults whose kidney transplants are being rejected by their immune system (antibody-mediated rejection). The trial has two parts: first, to find a safe dose, and second, to see if the drug can stop the rejection. About 58 people w…
Phase: PHASE1, PHASE2 • Sponsor: CASI pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for kidney transplant patients: belatacept trial targets hidden rejection
Disease control Not yet recruitingThis study tests whether switching to belatacept (a drug) plus standard care can better treat early antibody-mediated rejection in kidney transplant patients compared to continuing standard care alone. About 290 adults with new donor-specific antibodies but no kidney function dec…
Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kidney transplant patients: drug targets rejection
Disease control Not yet recruitingThis study tests a drug called mezagitamab in people who have had a kidney transplant and are experiencing a type of rejection called antibody-mediated rejection (AMR). AMR happens when the body's immune system attacks the donor kidney, which can lead to kidney failure. The study…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cooler for donor pancreas aims to improve transplant success
Disease control Not yet recruitingThis study will track 1000 people who receive a pancreas transplant to see if a special transport system (PancreasPak) helps the organ work better than standard methods. Researchers will compare rates of organ failure, hospital stay length, and survival up to one year after trans…
Sponsor: Paragonix Technologies • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug aims to stop kidney rejection
Disease control Not yet recruitingThis early study tests a new medicine called TNX-1500 in 5 people who get a kidney transplant. The goal is to see if it is safe and can help prevent the body from rejecting the new kidney. Participants will be followed for one year to check for side effects and signs of rejection…
Phase: PHASE2 • Sponsor: Ayman Al Jurdi, MD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Stem cell therapy fails to improve kidney rejection, raises safety flags
Disease control Not yet recruitingThis study tested whether a person's own stem cells (mesenchymal stem cells) could help treat chronic active antibody-mediated rejection in kidney transplant recipients. Only 3 patients were enrolled before the study was stopped early due to serious side effects. The treatment di…
Phase: NA • Sponsor: Shahid Beheshti University of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
AI takes on kidney transplant rejection in new pilot trial
Disease control Not yet recruitingThis pilot study tests whether an AI-based system can help doctors choose the right doses of immunosuppressant drugs for kidney transplant patients. The goal is to protect the new kidney from damage and rejection. The study will enroll 34 adults who have received a deceased donor…
Phase: NA • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Light therapy and donor cells aim to stop kidney rejection
Disease control Not yet recruitingThis early-stage trial tests whether giving kidney transplant recipients a special treatment made from their donor's cells, combined with a light-based therapy called photopheresis, can safely reduce the risk of organ rejection. About 24 adults receiving their first kidney transp…
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug could change kidney transplants forever
Disease control Not yet recruitingThis study tests a new drug called VEL-101 in 120 kidney transplant patients. The goal is to see if VEL-101 can safely replace the standard drug tacrolimus, which often causes side effects. Researchers will monitor for rejection, side effects, and how the drug behaves in the body…
Phase: PHASE2 • Sponsor: Veloxis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could a lupus drug unlock kidney transplants for Hard-to-Match patients?
Knowledge-focused Not yet recruitingThis study tests whether a short course of belimumab, a drug used for lupus, can improve detection of immune cells that cause transplant rejection. The goal is to help highly sensitized kidney transplant candidates—people whose immune systems are very picky about donor organs—get…
Phase: PHASE2 • Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC
-
Lung transplant study aims to predict treatment success faster
Knowledge-focused Not yet recruitingThis study looks for early signs that a treatment called ECP is working in people who have had a lung transplant and developed chronic rejection (CLAD). Researchers will collect blood samples and, for some, lung MRI scans before, during, and after ECP therapy. The goal is to find…
Sponsor: Brian Keller • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New study aims to unlock secrets of kidney transplant rejection
Knowledge-focused Not yet recruitingThis observational study at the University of Pittsburgh will enroll 24 kidney transplant recipients to deeply analyze why some rejections are stubborn. Researchers will use biopsies and blood samples to map immune cells and genetic changes. The goal is to better predict and unde…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Brain's own opioids may power placebo effect for heartbreak and pain
Knowledge-focused Not yet recruitingThis early-phase study investigates whether the opioid system is involved in placebo effects on both physical pain and the pain of social rejection. Sixty adults who recently experienced an unwanted breakup will receive either naloxone (which blocks opioids) or saline, and be tol…
Phase: EARLY_PHASE1 • Sponsor: Trustees of Dartmouth College • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Blood test may replace biopsies for kidney transplant patients
Knowledge-focused Not yet recruitingThis study follows 600 kidney transplant patients to see if a blood test (TruGraf and TRAC) can help doctors manage immunosuppression and detect early signs of rejection. The goal is to improve long-term outcomes by reducing the need for invasive biopsies. Participants will be mo…
Sponsor: Transplant Genomics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New MRI technique aims to spot kidney transplant rejection early
Knowledge-focused Not yet recruitingThis study will use advanced MRI scans to look at kidney transplants in 140 patients. The goal is to see if MRI can measure how well the kidney is working and tell the difference between stable function and problems like rejection. Researchers hope this could lead to a non-invasi…
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC